General and administrative expense for the year ended December 31, 2024 increased to $4.7 million, compared to $4.2 million for the year ended December 31, 2023 primarily due to increased salaries and ...

Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio ...

inhibitors, and STAT3 inhibitors as key weapons in the fight against cancer. As Moleculin Biotech advances its drug candidates through clinical trials, it holds the promise of bringing novel cancer ...

Session Date and Time: Monday, April 28, 2:00 - 5:00 p.m.

A drug typically prescribed for arthritis halts brain-damaging seizures in mice that have a condition like epilepsy, ...

They found a protein called STAT3, key to a cell signaling pathway ... your doctor has probably put you on what's called a JAK-inhibitor, a drug that's targeting this signaling pathway we're ...

Fintel reports that on March 25, 2025, Maxim Group upgraded their outlook for Moleculin Biotech (NasdaqCM:MBRX) from Hold to ...

Risk factors modification is crucial for diabetes care. Here, the authors show the relationships of combined modifiable risk factors with common complications of type 2 diabetes and provide ...